Mass Tort Advertising Campaign

Paraquat / Parkinsons Marketing & Claimant Acquisition

Paraquat Dichloride is one of the most widely used herbicides in American agriculture — and it sits at the center of a growing MDL alleging that occupational exposure to the chemical causes Parkinson's Disease. Manufacturers Syngenta and Chevron face claims from agricultural and farm workers who developed Parkinson's after years of handling or working near the substance. For plaintiff firms with capacity to work this docket, paid social acquisition is a proven mechanism to surface qualified claimants at scale.

Intake is currently open, and the claimant profile — rural, working-class, often without a direct attorney relationship — is precisely the audience that Facebook and Instagram reach efficiently. If your firm is evaluating a Paraquat campaign or looking to accelerate an existing docket, MTAA has the creative infrastructure and audience architecture to move quickly.

Book a strategy call All tort campaigns

Paraquat / Parkinsons at a glance

Substance / mechanism: Paraquat Dichloride
Manufacturer(s): Syngenta, Chevron
Associated injuries: Parkinson's Disease
Litigation status: Active MDL
Campaign intake: Open

The litigation landscape

The Paraquat litigation is consolidated as a federal MDL, with claims centered on the allegation that exposure to Paraquat Dichloride — manufactured and distributed by Syngenta and Chevron — causes Parkinson's Disease. Plaintiffs are predominantly agricultural workers: farmers, farm laborers, crop dusters, and others with direct or proximate occupational contact with the herbicide over extended periods. Parkinson's Disease, a progressive and irreversible neurological condition, is the singular injury at issue, giving this litigation a tight, medically coherent injury profile that supports focused intake screening.

The MDL posture means individual cases are being gathered and organized for bellwether proceedings, making this an active acquisition window for firms building or expanding their docket. The litigation draws natural comparisons to Roundup/glyphosate in structure — a widely used agricultural chemical, major agrochemical manufacturers, and a serious long-latency injury — but Paraquat's mechanism and the Parkinson's diagnosis create a distinct and arguably more medically direct narrative for claimant-facing creative.

Who a campaign targets

Agricultural and farm workers with documented or describable occupational exposure to Paraquat Dichloride — this is the core audience a campaign should prioritize.
Parkinson's Disease diagnosis — claimants must have a confirmed diagnosis; this is the non-negotiable injury anchor for intake qualification.
Ten or more years of exposure history — longer documented exposure strengthens case value and should be a primary qualification filter during intake.
Borderline consideration: Individuals with a family history of Parkinson's or limited documented exposure may warrant secondary review by intake counsel, but should not be the primary campaign target — firms should build their intake scripts to triage these profiles separately rather than exclude them outright at the ad level.

How MTAA runs Paraquat / Parkinsons campaigns

The creative strategy for Paraquat centers on two emotionally resonant facts: a familiar, widely used farm chemical and a devastating, recognizable disease. Unlike some mass torts where the injury is diffuse or contested, Parkinson's Disease is something most Americans have witnessed — in a parent, a neighbor, a coworker — which means claimant-facing creative can lead with the diagnosis and let the exposure history serve as the qualifier. Ad copy and video creative should speak directly to the agricultural community: farmers, ranch hands, migrant workers, and their families who may not realize that decades of herbicide exposure and a Parkinson's diagnosis are legally connected.

On the audience side, Meta's geographic and interest-based targeting allows MTAA to concentrate spend in high-density agricultural counties and rural markets where Paraquat use was historically concentrated — the same regions where Roundup campaigns have historically performed well, but with creative and landing-page messaging tailored specifically to Paraquat's chemical identity and the Parkinson's injury. Intake fit is strong: the qualification criteria are binary enough (exposure + diagnosis) that a well-structured lead form or intake call script can efficiently separate strong cases from borderline ones, keeping cost-per-qualified-lead manageable for firms with clear case criteria.

Pricing

Mass Tort Ad Agency runs Paraquat / Parkinsons campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.

Paraquat / Parkinsons advertising — common questions

How does Paraquat advertising differ from a Roundup campaign in terms of audience and creative?

Both torts target the agricultural community and share a similar geographic footprint, so there is audience overlap at the top of the funnel. The key creative distinction is the injury: Paraquat campaigns lead with Parkinson's Disease specifically, which carries strong name recognition and emotional weight, whereas Roundup creative typically centers on cancer diagnoses. Paraquat's more singular injury profile — one chemical, one disease — allows for tighter, more direct ad messaging and a cleaner intake qualification flow.

What does the ideal claimant profile look like for intake purposes, and how does that shape campaign targeting?

The strongest cases involve agricultural or farm workers with a Parkinson's Disease diagnosis and a substantial exposure history — ten or more years is the internal benchmark for a strong file. Campaign targeting should prioritize rural and agricultural geographies, with creative that prompts self-identification among people who worked directly with herbicides or on farms where Paraquat was applied. Intake scripts should be built to capture exposure duration and diagnosis documentation early in the qualification conversation.

Is the MDL status a reason to move quickly on acquisition, or does it create uncertainty?

MDL consolidation is generally a signal that the litigation has reached sufficient scale and organization to make docket-building worthwhile — bellwether proceedings create natural timelines that reward firms who have accumulated cases. For advertising purposes, open intake combined with an active MDL is the window where paid acquisition delivers the most value, before the litigation moves into phases that may restrict or slow case acceptance. Firms that build their docket now are better positioned as the MDL progresses.

How does MTAA handle the borderline claimant profiles — family history of Parkinson's or minimal documented exposure — at the campaign level?

At the ad and landing-page level, MTAA does not screen out borderline profiles — that is intake counsel's role, not the campaign's. Instead, we structure creative and lead forms to attract and flag the strongest signals (farm work, herbicide contact, Parkinson's diagnosis) while ensuring the intake team receives enough information to triage borderline leads appropriately. Firms should provide clear intake guidance on how they want those profiles handled so that campaign optimization can be calibrated toward the case types that convert for their docket.

Ready to run Paraquat / Parkinsons campaigns?

We build, run, and qualify Paraquat / Parkinsons claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.

Book a strategy call